Results 101 to 110 of about 1,100,787 (194)

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in ChinaResearch in context

EClinicalMedicine
Summary: Background: Effective time-limited therapies remain an unmet need in chronic lymphocytic leukaemia (CLL). We evaluated a novel regimen combining ibrutinib with intermittent fludarabine, cyclophosphamide, and rituximab (FCR) in patients with CLL.
Tingyu Wang, Yuting Yan, Hui Wang, Ying Sun, Xiantao Liu, Rui Lyu, Wenjie Xiong, Gang An, Wei Liu, Yan Xu, Shuhui Deng, Qi Wang, Chenxing Du, Liang Huang, Dehui Zou, Yaozhong Zhao, Lugui Qiu, Zengjun Li, Shuhua Yi   +18 more
doaj   +1 more source

Prospects for non-immunological molecular therapeutics in melanoma [PDF]

, 2010
In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Tryfonopoulos, Dimitrios, Eustace, Alexander J., Mahgoub, Thamir, O\u27Donovan, Norma, Crown, John, O'Donovan, Norma   +5 more
core   +2 more sources

Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia

Acta Haematologica Polonica
The combination of ibrutinib and venetoclax represents the first fixed-duration oral treatment involving a Bruton tyrosine kinase inhibitor and a BCL2 inhibitor for adult patients with untreated chronic lymphocytic leukaemia.
Elżbieta Iskierka-Jażdżewska, Krzysztof Jamroziak, Tadeusz Robak, Bartosz Puła   +3 more
doaj   +1 more source

Pituitary macroadenoma apoplexy as a rare complication of Bruton tyrosine kinase inhibitor in chronic lymphoid leukaemia. [PDF]

Chin Neurosurg J, 2023
Gomaa A, Skelly R.
europepmc   +1 more source

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. [PDF]

J Clin Oncol, 2023
Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN.   +36 more
europepmc   +1 more source

Rituximab combined with Bruton tyrosine kinase inhibitor to treat elderly diffuse large B-cell lymphoma patients: Two case reports. [PDF]

World J Clin Cases, 2023
Zhang CJ, Zhao ML.
europepmc   +1 more source

Mitigating Organophosphate Nerve Agent, Soman (GD)-Induced Long-Term Neurotoxicity: Saracatinib, a Src Tyrosine Kinase Inhibitor, as a Potential Countermeasure [PDF]

Background: Acute exposure to soman (GD), an organophosphate nerve agent (OPNA), irreversibly inhibits acetylcholinesterase (AChE), induces seizures, and could be fatal if not treated immediately. Existing medical countermeasures (MCMs- atropine, oximes,
Massey, Nyzil, Vasanthi, Suraj S, Im, Hyunmook, Bevoor, Avinash S, Holtkamp, Claire, Giménez-Lirola, Luis, Thippeswamy, Thimmasettappa, Wang, Chong, Kannurpatti, Sridhar, Rao, Nikhil S, Meyer, Christina   +10 more
core  

The clinical and biological consequences of different FLT3 mutations in patients with AML [PDF]

, 2009
Characterisation of pathogenic markers in acute myeloid leukaemia (AML) may benefit patients through refinement of risk stratification, application of molecularly targeted therapy and improved understanding of AML biology.
Mead, A.J.
core  

Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis. [PDF]

Sci Rep, 2023
Nguyen TT, Nhu NT, Tran VK, Viet-Nhi NK, Ho XD, Jhan MK, Chen YP, Lin CF.   +7 more
europepmc   +1 more source

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia

Therapeutics and Clinical Risk Management, 2015
David L Tucker, Simon A Rule Department of Haematology, Plymouth Hospitals NHS Trust, Plymouth, UK Abstract: Although chemo-immunotherapy remains at the forefront of first-line treatment for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia ...
Tucker DL, Rule SA
doaj